HUMA · NASDAQ
Humacyte (HUMA) Stock Price & Fundamentals
Humacyte (HUMA) closed at $869.19 on Oct 9, 2026, down 1.26% from the previous close of $880.29.
Share price, past year
1Y −4.67%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $869.19 |
| Sep 30, 2026 | $876.08 |
| Aug 31, 2026 | $914.14 |
| Jul 31, 2026 | $916.93 |
| Jun 30, 2026 | $880.01 |
| May 29, 2026 | $876.76 |
| Apr 30, 2026 | $884.01 |
| Mar 31, 2026 | $858.98 |
| Feb 27, 2026 | $828.08 |
| Jan 30, 2026 | $851.30 |
| Dec 31, 2025 | $863.21 |
| Nov 28, 2025 | $899.79 |
| Oct 31, 2025 | $914.99 |
Key statistics
- Market cap
- $241.46B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.55
- Revenue (TTM)
- $2.12M
- Net income (TTM)
- −$96.74M
- Shares outstanding
- 277.8M
- Dividend yield
- —
- 52-week range
- $808.49 – $929.30
Humacyte's market cap is $241.46B, based on a share price of $869.19 and 277.8M shares outstanding as of Jun 30, 2026.
Financials
Humacyte reported revenue of $2.04M for fiscal 2025.
Humacyte reported a net loss of $40.83M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $2.04M | — | −$40.83M | −2,003.6% | −$0.26 | −$105.93M |
| FY2024ended Dec 31, 2024 | $0.00 | — | −$148.70M | — | −$1.26 | −$99.69M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $406.00K | −$36.80M | −$0.16 |
| Q1 FY2026ended Mar 31, 2026 | $495.00K | −$17.62M | −$0.09 |
| Q4 FY2025ended Dec 31, 2025 | $467.00K | −$24.80M | −$0.19 |
| Q3 FY2025ended Sep 30, 2025 | $753.00K | −$17.51M | −$0.11 |
| Q2 FY2025ended Jun 30, 2025 | $301.00K | −$37.66M | −$0.24 |
| Q1 FY2025ended Mar 31, 2025 | $517.00K | $39.14M | $0.28 |
| Q4 FY2024ended Dec 31, 2024 | $0.00 | −$20.94M | −$0.16 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$39.20M | −$0.33 |
Company profile
- Name
- Humacyte, Inc.
- Ticker
- HUMA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 2525 East North Carolina Highway 54, Durham, NC 27713
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001818382
Recent SEC filings
- Sep 28, 2026
- Aug 12, 2026
- Aug 12, 2026
- Jul 31, 2026
- Jun 11, 2026
- Jun 10, 2026
- Jun 9, 2026
- Jun 5, 2026
Frequently asked questions
What is Humacyte's stock price?
Humacyte (HUMA) closed at $869.19 on Oct 9, 2026, down 1.26% from the previous close of $880.29.
What is Humacyte's market cap?
Humacyte's market cap is $241.46B, based on a share price of $869.19 and 277.8M shares outstanding as of Jun 30, 2026.
How much revenue does Humacyte make?
Humacyte reported revenue of $2.04M for fiscal 2025.
Does Humacyte pay a dividend?
Humacyte's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Humacyte, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures